Brilliant Violet 785™ anti-human CD68

Antibodies Single
Sony
Y1/82A
Intracellular Flow Cytometry
Mouse IgG2b, κ
Human
2269125
$226.00

Description

CD68 is a 110 kD glycoprotein, also known as macrosialin, belonging to the sialomucin family. It is closely related to the family of acidic, highly glycosylated lysosomal-associated membrane proteins (LAMPs). CD68 is predominately expressed in cytoplasmic granules of monocytes/macrophages, dendritic cells, and granulocytes. It is one of the useful myeloid cell markers. Further studies have shown that CD68 is also expressed by a subset of hematopoietic progenitors, γ/δ T cells, NK cells, LAK cells, subset of B cells, fibroblasts, and endothelial cells. The biological function of CD68 is still unknown.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

  1. Doussis IA, et al. 1993. J. Clin. Pathol. 46:334.
  2. Davey FR, et al. 1988. J. Clin. Pathol. 41:753.
  3. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110. (IF) PubMed